**Supplementary Material for** "Optimal SARS-CoV-2 vaccine distribution using real-time sereprevalence estimates in Rhode Island and Massachusetts"

Tran, Wikle, Albert, et al.

Date of this draft: January 10, 2021.



Figure S1: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 180 days under low transmission setting in Rhode Island.



Figure S2: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 360 days under low transmission setting in Rhode Island.



Figure S3: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under low transmission setting in Rhode Island.



Figure S4: Similar to Figure 6, analysis of different dose allocations for strategies focused on the 20-49 and 70+ age groups, ranging from a 10/90 allocation (90% of vaccines initially given to 70+ age group) to a 90/10 allocation (90% of vaccines initially given to 20-49 age group) under **low** transmission setting in **Rhode Island**.



Figure S5: Similar to Figure 7, comparison of vaccinating all individuals and vaccinating only antibody-negative individuals under **low** transmission setting in **Rhode Island**.



Figure S6: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 360 days under medium transmission setting in Rhode Island.



Figure S7: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under medium transmission setting in Rhode Island.



Figure S8: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 180 days under high transmission setting in Rhode Island.



Figure S9: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 360 days under high transmission setting in Rhode Island.



Figure S10: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under high transmission setting in Rhode Island.



Figure S11: Similar to Figure 6, analysis of different dose allocations for strategies focused on the 20-49 and 70+ age groups, ranging from a 10/90 allocation (90% of vaccines initially given to 70+ age group) to a 90/10 allocation (90% of vaccines initially given to 20-49 age group) under **high** transmission setting in **Rhode Island**.



Figure S12: Similar to Figure 7, comparison of vaccinating all individuals and vaccinating only antibody-negative individuals under **high** transmission setting in **Rhode Island**.



Figure S13: Similar to Figure 4, impact of including (blue) or excluding (orange) each age group in a vaccination policy, measured as reductions in cumulative cases, hospitalizations, and deaths in **Massachusetts** by 30 June 2021.

![](_page_14_Figure_0.jpeg)

Figure S14: Similiar to Figure 3, dynamics of SARS-CoV-2 epidemic in **Massachusetts** under three different transmission scenarios and ten vaccination strategies. The vaccine profile shown here has efficacy half-life of 180 days and slope of 2. The vaccination campaign covers 1,800,000 people (26.1% population coverage) and ends on 04 March 2021. The last row shows seroprevalence in Massachusetts from August 15, 2020 to 30 June, 2021. With no vaccination, seroprevalence would reach 28.3%, 40.1%, and 54.4% by June 30, 2021 under low, medium, and high transmission settings, respectively.

![](_page_15_Figure_0.jpeg)

Figure S15: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of **180** days under **low** transmission setting in **Massachusetts**. The vaccine supply shown in the first three columns is 300,000 which is enough to cover 4.3% of Massachusetts population. The last three columns show results with 1,800,000 cumulative vaccinations (26.1% population). We use "random" (solid gray), where everybody is equally likely to receive the vaccine, as the reference strategy.

![](_page_16_Figure_0.jpeg)

Figure S16: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of **360** days under low transmission setting in Massachusetts.

![](_page_17_Figure_0.jpeg)

Figure S17: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under low transmission setting in Massachusetts.

![](_page_18_Figure_0.jpeg)

Figure S18: Similar to Figure 6, analysis of different dose allocations for strategies focused on the 20-49 and 70+ age groups, ranging from a 10/90 allocation (90% of vaccines initially given to 70+ age group) to a 90/10 allocation (90% of vaccines initially given to 20-49 age group) under low transmission setting in Massachusetts.

![](_page_19_Figure_0.jpeg)

Figure S19: Similar to Figure 7, comparison of vaccinating all individuals and vaccinating only antibody-negative individuals under low transmission setting in Massachusetts.

![](_page_20_Figure_0.jpeg)

Figure S20: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of **180** days under **medium** transmission setting in **Massachusetts**. The vaccine supply shown in the first three columns is 300,000 which is enough to cover 4.3% of Massachusetts population. The last three columns show results with 1,800,000 cumulative vaccinations (26.1% population). We use "random" (solid gray), where everybody is equally likely to receive the vaccine, as the reference strategy.

![](_page_21_Figure_0.jpeg)

Figure S21: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 360 days under medium transmission setting in Massachusetts.

![](_page_22_Figure_0.jpeg)

Figure S22: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under medium transmission setting in Massachusetts.

![](_page_23_Figure_0.jpeg)

Figure S23: Similar to Figure 6, analysis of different dose allocations for strategies focused on the 20-49 and 70+ age groups, ranging from a 10/90 allocation (90% of vaccines initially given to 70+ age group) to a 90/10 allocation (90% of vaccines initially given to 20-49 age group) under **medium** transmission setting in **Massachusetts**.

![](_page_24_Figure_0.jpeg)

Figure S24: Similar to Figure 7, comparison of vaccinating all individuals and vaccinating only antibody-negative individuals under **medium** transmission setting in **Massachusetts**.

![](_page_25_Figure_0.jpeg)

Figure S25: Similar to Figure 5, comparison of ten vaccination strategies vaccine efficacy half-life of **180** days under **high** transmission setting in **Massachusetts**. The vaccine supply shown in the first three columns is 300,000 which is enough to cover 4.3% of Massachusetts population. The last three columns show results with 1,800,000 cumulative vaccinations (26.1% population). We use "random" (solid gray), where everybody is equally likely to receive the vaccine, as the reference strategy.

![](_page_26_Figure_0.jpeg)

Figure S26: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 360 days under high transmission setting in Massachusetts.

![](_page_27_Figure_0.jpeg)

Figure S27: Similar to Figure 5, comparison of ten vaccination strategies with vaccine efficacy half-life of 540 days under high transmission setting in Massachusetts.

![](_page_28_Figure_0.jpeg)

Figure S28: Similar to Figure 6, analysis of different dose allocations for strategies focused on the 20-49 and 70+ age groups, ranging from a 10/90 allocation (90% of vaccines initially given to 70+ age group) to a 90/10 allocation (90% of vaccines initially given to 20-49 age group) under **high** transmission setting in **Massachusetts**.

![](_page_29_Figure_0.jpeg)

Figure S29: Similar to Figure 7, comparison of vaccinating all individuals and vaccinating only antibody-negative individuals under **high** transmission setting in **Massachusetts**.